Healthcare major Eli Lilly and Company has confirmed that the products recently seized by Haryana drug control authority were counterfeit products falsely bearing the Mounjaro® (tirzepatide) brand name.
The products were recently seized from Gurugram, Haryana. “These seized counterfeit products were not manufactured by Lilly and did not originate from Lilly’s authorised and verified supply chain,” the company said.
Most of the identified counterfeit products have been recovered by the authorities, the company said, urging people to buy the product only from authorised outlets.
“In line with directions issued by the authority, the supply of genuine Lilly product through authorised distributors and licensed pharmacies continues without interruption.”
Winselow Tucker, President and General Manager, Eli Lilly and Company (India), said, “Counterfeit products are not manufactured under approved quality controls and may pose significant risks to patient safety and public health. We will continue to take steps to protect patients from the risks of counterfeit and other unsafe products worldwide, including working with regulators and law enforcement. We urge patients to procure Lilly products only through authorised distributors or licensed pharmacies, and on a valid prescription.”
Further, Lilly said, its patented tirzepatide molecule is marketed in India under two brand names — Mounjaro® and Yurpeak®.”